Technical Analysis for CALC - CalciMedica, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 3.45 | 2.99% | 0.10 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 2.99% | |
| Oversold Stochastic | Weakness | 2.99% | |
| Stochastic Buy Signal | Bullish | 2.07% | |
| Narrow Range Bar | Range Contraction | 2.07% | |
| Inside Day | Range Contraction | 2.07% |
| Alert | Time |
|---|---|
| Rose Above 10 DMA | about 21 hours ago |
| Up 2% | about 21 hours ago |
| Up 1% | about 21 hours ago |
| 60 Minute Opening Range Breakdown | 1 day ago |
| Down 2 % | 1 day ago |
Free Daily (Stock) Chart Reading
- Earnings date: 11/07/2024
CalciMedica, Inc. Description
CalciMedica is a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need. CalciMedica’s proprietary technology targets the inhibition of calcium release-activated calcium (CRAC) channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases for which there are currently no approved therapies. CalciMedica’s lead product candidate Auxora, a proprietary, intravenous-formulated CRAC channel inhibitor, has demonstrated positive and consistent clinical results in four completed efficacy clinical trials. Auxora is in development for acute pancreatitis and asparaginase-associated pancreatitis. CalciMedica was founded by scientists from Torrey Pines Therapeutics and the Harvard CBR Institute for Biomedical Research, and is headquartered in La Jolla, CA.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Medication Inflammatory Diseases Abdominal Pain Pancreatitis Acute Pancreatitis Asparaginase
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 8.38 |
| 52 Week Low | 2.68 |
| Average Volume | 49,526 |
| 200-Day Moving Average | 4.50 |
| 50-Day Moving Average | 3.97 |
| 20-Day Moving Average | 3.64 |
| 10-Day Moving Average | 3.42 |
| Average True Range | 0.25 |
| RSI (14) | 42.53 |
| ADX | 10.13 |
| +DI | 20.59 |
| -DI | 20.75 |
| Chandelier Exit (Long, 3 ATRs) | 4.77 |
| Chandelier Exit (Short, 3 ATRs) | 4.02 |
| Upper Bollinger Bands | 4.35 |
| Lower Bollinger Band | 2.94 |
| Percent B (%b) | 0.36 |
| BandWidth | 38.78 |
| MACD Line | -0.19 |
| MACD Signal Line | -0.19 |
| MACD Histogram | -0.0022 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.59 | ||||
| Resistance 3 (R3) | 3.57 | 3.51 | 3.56 | ||
| Resistance 2 (R2) | 3.51 | 3.48 | 3.52 | 3.55 | |
| Resistance 1 (R1) | 3.48 | 3.45 | 3.50 | 3.50 | 3.55 |
| Pivot Point | 3.42 | 3.42 | 3.43 | 3.43 | 3.42 |
| Support 1 (S1) | 3.39 | 3.39 | 3.41 | 3.41 | 3.35 |
| Support 2 (S2) | 3.33 | 3.36 | 3.34 | 3.35 | |
| Support 3 (S3) | 3.30 | 3.33 | 3.34 | ||
| Support 4 (S4) | 3.32 |
